A detailed history of Royal Bank Of Canada transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 42,078 shares of IGMS stock, worth $438,873. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,078
Previous 22,340 88.35%
Holding current value
$438,873
Previous $153,000 354.25%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.28 - $17.68 $123,954 - $348,967
19,738 Added 88.35%
42,078 $695,000
Q2 2024

Aug 14, 2024

BUY
$6.51 - $11.47 $143,467 - $252,775
22,038 Added 7297.35%
22,340 $153,000
Q1 2024

Nov 05, 2024

SELL
$8.68 - $17.36 $191,289 - $382,579
-22,038 Reduced 98.65%
302 $2,000
Q1 2024

May 15, 2024

SELL
$8.68 - $17.36 $46,967 - $93,934
-5,411 Reduced 94.71%
302 $2,000
Q4 2023

Feb 14, 2024

SELL
$3.94 - $8.79 $1,930 - $4,307
-490 Reduced 7.9%
5,713 $47,000
Q3 2023

Nov 14, 2023

BUY
$6.66 - $10.64 $5,048 - $8,065
758 Added 13.92%
6,203 $51,000
Q2 2023

Aug 14, 2023

BUY
$8.86 - $14.0 $4,899 - $7,742
553 Added 11.3%
5,445 $50,000
Q1 2023

May 15, 2023

SELL
$13.74 - $25.76 $6,911 - $12,957
-503 Reduced 9.32%
4,892 $67,000
Q4 2022

Feb 14, 2023

BUY
$15.45 - $26.02 $16,469 - $27,737
1,066 Added 24.62%
5,395 $91,000
Q3 2022

Nov 14, 2022

BUY
$15.42 - $27.01 $35,034 - $61,366
2,272 Added 110.45%
4,329 $99,000
Q2 2022

Aug 15, 2022

SELL
$13.27 - $25.5 $5,918 - $11,373
-446 Reduced 17.82%
2,057 $37,000
Q1 2022

May 16, 2022

SELL
$13.42 - $29.73 $15,406 - $34,130
-1,148 Reduced 31.44%
2,503 $66,000
Q4 2021

Feb 14, 2022

SELL
$27.59 - $66.39 $692,315 - $1.67 Million
-25,093 Reduced 87.3%
3,651 $107,000
Q3 2021

Nov 15, 2021

BUY
$65.76 - $90.65 $8,088 - $11,149
123 Added 0.43%
28,744 $1.89 Million
Q2 2021

Aug 16, 2021

BUY
$57.98 - $96.6 $1.66 Million - $2.76 Million
28,621 New
28,621 $2.38 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $302M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.